Skip to content

The effect of Local Infiltration Analgesia on postoperative pain in Total Knee Arthroplastia

The effect of Local Infiltration Analgesia on postoperative pain in Total Knee Arthroplastia - TOKNOWIT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36098
Enrollment
82
Registered
2011-07-12
Start date
2011-11-25
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

Controlgroup: standard care: Peroperative placebo infiltration, postoperative Patient Controlled Analgesia (PCA) with morfine during 20 hours. Interventiongroup: peroperative peri- en intraarticular

Sponsors

Meander Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age > 18 years Total knee arthroplastia of one knee Short track program

Exclusion criteria

Exclusion criteria: revision of former total knee arthroplastia, chronic use of opioids, use of steroids, bilateral surgery, contra-indication for spinal or epidural analgesia, ASA-score > 3, time of surgery > 2 hours, intolerance of study medication, epilepsia, sensibility disorder of the leg, former patellectomy, (acute of chronic) infection of the knee, psychiatric illness, neuromuscular effects, language barrier, immunologic disease, BMI > 40, alcohol abusus, pregnant women,

Design outcomes

Primary

MeasureTime frame
VAS-score 6 hours after operation

Secondary

MeasureTime frame
Pain management: need for opiates in the first 24 hours, incidence of severe pain (NRS >7) in the first 24 hours, VAS-score whilest leaving recovery, the evening after surgery and the first 4 days measured 3 times a day. Side effects: incidence and severity of nausea and vometing Recovery: MILAS assistance scale, flexion of knee, hospital stay

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)